Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing

Karuna Therapeutics’ multi-year mission to resurrect an old Eli Lilly drug has ended in clinical success. The biotech has emerged from the phase 3 Emergent-2 trial with evidence showing its therapy works in schizophrenia, positioning it to seek FDA approval next year.